Afinitor contains the active ingredient everolimus and may not be safe to take during pregnancy and breastfeeding. Keep reading for specific information about reproductive health and Afinitor.

Afinitor (everolimus) is a prescription drug that’s used to treat some types of cancer, seizures, and certain tumors. This drug can interact with other medications and some supplements.

Patients with previously treated advanced clear cell renal cell carcinoma (RCC) — a type of kidney cancer — experienced improvements in progression and response via treatment with Welireg (belzutifan) ...

While Welireg (belzutifan) has outperformed Afinitor (everolimus) in OS at 12 months and 24 months, the results have not achieved statistical significance. The OS gap between Welireg and Afinitor ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

and cancer chemotherapy Afinitor (everolimus) under Medicare. Novartis said last year it had set aside $700 million for a possible settlement for the allegations, which cover a period between 2002 ...

Lenvima is approved as monotherapy in thyroid cancer, as well as in combination with Novartis’ Afinitor (everolimus) for renal cell carcinoma who have failed previous therapy. The tie-up follows ...

Treatment with belzutifan (Welireg) demonstrated significant benefits over everolimus (Afinitor) in treating advanced clear cell renal cell carcinoma (RCC). Specifically, patients who received ...

Regarding chromophobe RCC, Albiges showed data on the combinations of lenvatinib/everolimus (Afinitor) (n = 9) and lenvatinib/pembrolizumab (n = 29), which reported an ORR of 44% vs 34.5%, ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...